Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.
Back
The Evolving Treatment Paradigm for Platinum-Resistant Ovarian Cancer
Floortje J Backes, MD, discusses evolving treatment considerations for platinum-resistant ovarian cancer.
The Evolving Treatment Paradigm for Platinum-Resistant Ovarian Cancer
Episodes
All
All
Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.
Floortje J. Backes, MD, discusses data for mirvetuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
Floortje J. Backes, MD, discusses other potential roles for mirvetuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis
5